Is the price fair?
What BBIO's price assumes
BridgeBio Pharma, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 24.9× revenue.
24.9
Price / sales · no P/E: the last twelve months did not end in a profit
- EV / sales
- 28.0
EV / sales
Details›
- EV / EBIToperating margin −70%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 28.0
- Market capitalisation
- $13.0B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.